Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Intradigm demonstrates delivery system for cancer treatment

Intradigm : 24 October, 2007  (New Product)
Intradigm has demonstrated the company’s TargeTran delivery system is capable of delivering vascular endothelial growth factor (VEGF) targeted small interfering RNAs (siRNAs) that suppress tumour-induced angiogenesis by silencing target gene expression in mice.
Complete study findings were presented by Intradigm scientists at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

This preclinical study was designed to examine the anti-angiogenic efficacy, in multiple cancer types, of VEGF-targeted siRNAs administered systemically with Intradigm’s proprietary RNAi Nanoplex delivery technology using the TargeTran delivery system. At the study’s outset, tumour cells (both human colorectal and renal cell carcinoma) were implanted into a group of mice.

At both two and five days post tumour cell introduction, a portion of the mice were given intravenous (IV) administration of several siRNAs targeting VEGF ligand, VEGFR1, VEGFR2, or various combinations of the three. The remaining mice received either a negative control siRNA treatment or a positive control treatment using VEGF antibody Bevacizumab.

At eight days, tumour-induced angiogenesis as well as target gene knockdown were analysed. The results showed highly significant anti-angiogenic effect that is RNAi-mediated in all active siRNA treatment groups targeting different VEGF-pathways genes.

“These study results are very encouraging as they demonstrate the ability of our RNAi Nanoplex technology to systemically deliver siRNA therapeutics directly to tumour vasculature and tumour cells,” said Mohammad Azab, MD, president and chief executive officer of Intradigm. “The targeting of the VEGF pathway with RNAi represents a novel approach for anti-angiogenesis-based therapeutics, and with the tumour selectivity offered by our TargeTran system, we believe we are developing an innovative therapeutic candidate that may possess efficacy and/or safety advantages over existing or other anti-angiogenic agents in development.”

ICS-283 is currently in preclinical development for a variety of cancer indications and the company expects to initiate clinical development of this candidate in 2008.

The findings support data from several other in vivo models, including xenograft models of different cancers, which have confirmed an RNAi-mediated anti-angiogenic effect following systemic administration similar to VEGF antibody. VEGF, as an established target in the treatment of cancer, provides a clear clinical development path to validate the success of Intradigm’s systemic delivery of siRNA in man.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo